Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: A randomized, single-blind, placebo-controlled trial

Advances in Therapy

Volumn 31, Issue 3, 2014, Pages 345-361

  Sasaki, Takashi ^a   Seino, Yutaka ^b   Fukatsu, Atsushi ^c   Sakai, Soichi ^d   Samukawa, Yoshishige ^d  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c Yachiyo Hospital   (Japan)

^d TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

First in human; Healthy Japanese subjects; Luseogliflozin; Phase 1 studies; Sodium glucose cotransporter 2 (SGLT2); TS 071; Type 2 diabetes mellitus; Urinary glucose excretion

Indexed keywords

GLUCOSE; LUSEOGLIFLOZIN; PLACEBO; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SORBITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FIRST IN HUMAN STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; OCCULT BLOOD; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URETHRITIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; HALF LIFE TIME; JAPAN; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLYCOSURIA; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; SINGLE-BLIND METHOD; SORBITOL; YOUNG ADULT;

EID: 84898890575     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0102-3     Document Type: Article

References (39)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th edn. 2011/2012 update. Available from: http://www.idf.org/diabetesatlas/. Accessed 19 Nov 2013.
2. Ministry of Health, Labour and Welfare. Summary of Patient Survey 2008. Available from: http://www.mhlw.go.jp/english/database/db-hss/sps-2008.html. Accessed 19 Nov 2013
3. National Institute of Health and Nutrition. Outline of the National Health and Nutrition Survey Japan, 2007. Available from: http://www0.nih.go.jp/ eiken/english/research/project-nhns.html/. Accessed 19 Nov 2013.
4. Fukushima S, Nakagami T, Suto C, Hirose A, Uchigata Y. Prevalence of retinopathy and its risk factors in a Japanese population. J Diabetes Investig. 2013;4:349-54.
5. Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: a questionnaire survey of 18385 diabetics over a 10-year period. J Diabetes Investig. 2010;1:66-76.
6. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4-18.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65.
10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.
11. Nauck MA, Vardarli I. Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig. 2010;1:24-36.
12. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12.
13. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-6.
14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
15. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32-43.
16. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Investig. 1994;93:397-404.
17. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.
18. Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig. 2012;3:352-3.
19. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013;139:51-9.
20. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723-9.
21. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
22. Dapagliflozin (Forxiga): EU summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/27188/SPC/ Forxiga+5%20mg++%26+10+mg+film+coated+tablets/. Accessed 19 Nov 2013.
23. Canagliflozin (Invokana): prescribing information. Available from: http://www.invokanahcp.com/prescribing-information.pdf/. Accessed 19 Nov 2013.
24. Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol. 2011;164(1):181-91.
25. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010;53:3247-61.
26. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
27. English translation of Attachment 1 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012. Guideline for Bioequivalence Studies of Generic Products. Available from: http://www.nihs.go.jp/drug/be-guide(e)/Generic/GL-E-120229-BE.pdf. Accessed 28 Jan 2014.
28. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167-71.
29. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173-8.
30. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
31. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.
32. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-33.
33. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:473-8.
34. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:479-84.
35. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357-65.
36. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669-72.
37. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213-9.
38. Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2:172-82.
39. Carlson MG, Snead WL, Campbell PJ. Fuel and energy metabolism in fasting humans. Am J Clin Nutr. 1994;60:29-36.